

alpelisib (PIQRAY)

Diagnosis Considered for Coverage:

- Hormone receptor (HR)-positive HER2-negative PIK3CA-mutated, advanced, recurrent, or metastatic breast cancer

Coverage Criteria:

For diagnosis listed above:

- Being used for advanced, recurrent, or metastatic breast cancer, **and**
- Patient is hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and PIK3CA-mutated, **and**
- Patient is either a male OR female that is postmenopausal or is receiving hormonal suppression therapy (e.g. oophorectomy [removal of ovaries], goserelin, Zoladex, leuprolide, Lupron), **and**
- Being used as second line therapy or beyond, **and**
- Being used in combination with Faslodex (fulvestrant), **and**
- The dose does not exceed 300 mg per day.

Coverage Duration: one year

Effective Date: 09/27/2023